Sequoia Financial Advisors LLC raised its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 17.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,293 shares of the medical research company’s stock after buying an additional 1,412 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Amgen were worth $1,884,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Salomon & Ludwin LLC raised its stake in Amgen by 125.0% during the fourth quarter. Salomon & Ludwin LLC now owns 108 shares of the medical research company’s stock valued at $26,000 after buying an additional 60 shares during the last quarter. Savior LLC bought a new stake in shares of Amgen in the 4th quarter worth $34,000. CLS Investments LLC increased its holdings in shares of Amgen by 175.4% in the 4th quarter. CLS Investments LLC now owns 157 shares of the medical research company’s stock worth $38,000 after purchasing an additional 100 shares in the last quarter. Altshuler Shaham Ltd increased its holdings in shares of Amgen by 273.9% in the 4th quarter. Altshuler Shaham Ltd now owns 172 shares of the medical research company’s stock worth $42,000 after purchasing an additional 126 shares in the last quarter. Finally, Sageworth Trust Co bought a new stake in shares of Amgen in the 4th quarter worth $42,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
In other Amgen news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $237.31, for a total transaction of $100,856.75. Following the sale, the director now directly owns 5,834 shares in the company, valued at $1,384,466.54. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronald D. Sugar sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $229.27, for a total value of $229,270.00. Following the sale, the director now owns 16,482 shares in the company, valued at $3,778,828.14. The disclosure for this sale can be found here. Insiders sold 2,425 shares of company stock worth $563,477 over the last quarter. 0.25% of the stock is owned by company insiders.
Shares of NASDAQ:AMGN traded up $1.65 during mid-day trading on Friday, reaching $226.43. The stock had a trading volume of 2,305,494 shares, compared to its average volume of 2,887,619. The company has a current ratio of 1.59, a quick ratio of 1.28 and a debt-to-equity ratio of 3.16. The company has a market cap of $132.23 billion, a P/E ratio of 17.75, a price-to-earnings-growth ratio of 1.92 and a beta of 0.97. Amgen, Inc. has a 1 year low of $166.68 and a 1 year high of $244.99. The business’s 50 day moving average price is $228.36 and its 200 day moving average price is $225.14.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of $3.70 by $0.47. The company had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $6.01 billion. Amgen had a return on equity of 90.75% and a net margin of 32.03%. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the previous year, the business earned $3.56 earnings per share. Analysts predict that Amgen, Inc. will post 15.58 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 8th. Investors of record on Monday, May 18th will be given a $1.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.83%. Amgen’s dividend payout ratio is currently 43.18%.
A number of analysts have commented on the company. Oppenheimer assumed coverage on Amgen in a report on Friday, May 1st. They issued a “buy” rating and a $252.00 target price for the company. Piper Sandler lifted their target price on Amgen from $235.00 to $255.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Mizuho reaffirmed a “hold” rating and issued a $215.00 price objective on shares of Amgen in a report on Thursday, April 30th. Finally, ValuEngine raised Amgen from a “sell” rating to a “hold” rating in a report on Tuesday, March 3rd. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and seventeen have given a buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and an average target price of $244.65.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: Cost of Debt
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.